Concord Repatriation General Hospital Report issue

Academic/Hospital Phase 2 Phase 3

Organization Overview

First Clinical Trial
2018
NCT03998319
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2023

Timeline

NOW
  • Now

Alternative names

Concord Repatriation General Hospital

Active Ingredients

Drugs in Phase 3 Trials (1)

tenecteplase (tnkase) (1 trial)

Drugs in Phase 2 Trials (1)

ambroxol (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

ST Elevation Myocardial Infarction (Phase 3)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 2
  • # of Trial APIs: 2